21 February 2026
Johnson & Johnson's TREMFYA® Shows Sustained Remission in Ulcerative Colitis Over 3 Years
TREMFYA® maintains clinical, endoscopic, and histologic outcomes in ulcerative colitis through 140 weeks, with high patient retention and no new safety concerns.
